SciClone Q2 Revenue Up; Expects $35M to $36M for 2007
SciClone Q2 Revenue Up; Expects $35M to $36M for 2007 « H E » MN1 Exclusive :: email posted Tuesday, 7 August 2007 MN1 Staff WriterModerate trading activity for SciClone Pharmaceuticals Inc. (Nasdaq: SCLN) on the eve of its second quarter earnings announcement as the stock closed down 2 cents at $2.14 per share. SciClone reported its second quarter earnings before the opening bell today. For the second quarter 2007, product revenues from the sale of ZADAXIN (thymalfasin), SciClone's lead product, increased by 13 percent to $9 million, compared with revenues of $7.9 million for the second quarter 2006. The…